The commercialisation of bio-synthesised cannabidiol could be on the horizon following the announcement by Amyris that it will be forming a new partnership to focus on “cannabinoid development”. The California-based company is best known for creating synthetic sweeteners and medicines from sugars using a yeast-based process, and it is thought it will do the same with CBD. While the company » Continue Reading....
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
LATEST ALERTS
